

ajanta pharma limited

INVESTOR PRESENTATION

Q1 FY 2022

(29th July 2021)

1 of 27 **ajanta**

Safe Harbor Statement

This presentation may include certain 'forward looking statements', based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.


The Company disclaims any obligation to revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.


This material is used during oral presentation; it is not a complete record of the discussion.

2021


ajanta


















	Mar 2005	June 2020	June 2021	
Ophthalmology	28	2	2	
Dermatology	98	15	15	
Cardiology	38	17	18	
Pain Management	NA	36	33	
Ajanta Pharma	88	29	29	

















Research & Development



Q1 FY 2021 Rs. 31 cr. (5%) Q1 FY 2022 Rs. 45 cr. (6%)









17 of 27 ajanta

Manufacturing

Formulation Manufacturing

- 3 facilities at Aurangabad, Maharashtra
- 1 facility at Dahej, Gujarat
- 1 facility at Guwahati, Assam
- 1 facility at Pithampur, Madhya Pradesh
- 1 facility at Mauritius

API Manufacturing

 1 facility at Waluj, Aurangabad, Maharashtra (Captive Consumption)



Sterile Ophthalmic line



Packing Machine



Tablet Compression Machine

aiani

July 2021



Rs. cr.	Q1 FY 2021	% to RO	Q1 FY 2022	% to RO
Revenue from Operations (RO)	668	70 to 100	748	70 to 100
Other Income	13	2%	33	4%
Total Income	681	270	781	470
Materials consumed	152	23%	171	23%
Employee Benefit	136	20%	158	21%
Finance Cost	2	0%	2	0%
Depreciation	28	4%	31	4%
Other Expenses	156	23%	198	26%
Total Expenses	474	70%	560	75%
Profit Before Tax	207	31%	221	29%
Tax Expense	59	9%	47	6%
Net Profit	148	22%	174	23%
Other Comprehensive Income	1	0%	(3)	0%
Total Comprehensive Income	149	22%	171	23%
EBITDA	223	33%	220	29%

▶ P&L Synopsis – Q1 FY 2022 (Consolidated)

Rs. cr.	Q1 FY 2021	%	Q1 FY 2022	%	% Growth
Exports	483	72%	513	68%	6%
Domestic	174	26%	229	31%	32%
Other Op. Income	11	2%	6	1%	(43%)
Revenue from Operations	668		748		12%
EBITDA	223	33%	220	29%	(1%)
PBT	207	31%	221	29%	7%
PAT	148	22%	174	23%	18%
Total Comprehensive Income	149	22%	171	23%	15%


21 of 27 **ajanta**











Thank You

For more information please visit our website:

www.ajantapharma.com

For regular updates follow us on twitter

www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal - 022-66061377 rajeev.agarwal@ajantapharma.com

Abhineet Kumar – 022-66061814 abhineet.kumar@ajantapharma.com

Ajanta House, Charkop, Kandivli (W), Mumbai 400 067 CIN No. - L24230MH1979PLC022059

ajanta